CN112851510A - Purification method of tafluprost - Google Patents
Purification method of tafluprost Download PDFInfo
- Publication number
- CN112851510A CN112851510A CN202110111991.0A CN202110111991A CN112851510A CN 112851510 A CN112851510 A CN 112851510A CN 202110111991 A CN202110111991 A CN 202110111991A CN 112851510 A CN112851510 A CN 112851510A
- Authority
- CN
- China
- Prior art keywords
- tafluprost
- solvent
- purification method
- ethyl acetate
- silica gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 title claims abstract description 155
- 229960004458 tafluprost Drugs 0.000 title claims abstract description 155
- 238000000034 method Methods 0.000 title claims abstract description 67
- 238000000746 purification Methods 0.000 title claims description 62
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 45
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 29
- 239000012043 crude product Substances 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 168
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 109
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 95
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 54
- 239000002904 solvent Substances 0.000 claims description 54
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 45
- 239000013557 residual solvent Substances 0.000 claims description 34
- 239000012046 mixed solvent Substances 0.000 claims description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 17
- 239000000741 silica gel Substances 0.000 claims description 17
- 229910002027 silica gel Inorganic materials 0.000 claims description 17
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 16
- 229940127557 pharmaceutical product Drugs 0.000 claims description 16
- 239000002798 polar solvent Substances 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 15
- 239000003480 eluent Substances 0.000 claims description 12
- 239000012454 non-polar solvent Substances 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 11
- 239000011148 porous material Substances 0.000 claims description 11
- 238000004007 reversed phase HPLC Methods 0.000 claims description 7
- 208000022873 Ocular disease Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010030043 Ocular hypertension Diseases 0.000 claims description 2
- 239000012535 impurity Substances 0.000 description 15
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 14
- 238000004817 gas chromatography Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000003960 organic solvent Substances 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- KIQXRQVVYTYYAZ-VKVYFNERSA-N (z)-7-[(1r,2r,3r,5s)-2-[(e)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid Chemical compound OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 KIQXRQVVYTYYAZ-VKVYFNERSA-N 0.000 description 8
- -1 -isopropyl 5-heptenoate Chemical compound 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000000354 decomposition reaction Methods 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000013341 scale-up Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- SJHMQXMERUQDSR-BNBDNKSYSA-N (3ar,4r,5r,6as)-4-[(e)-3,3-difluoro-4-phenoxybut-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one Chemical compound C(/[C@@H]1[C@H]2CC(=O)O[C@H]2C[C@H]1O)=C\C(F)(F)COC1=CC=CC=C1 SJHMQXMERUQDSR-BNBDNKSYSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 238000004305 normal phase HPLC Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000000790 scattering method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/56—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
- C07C67/54—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation by distillation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
- C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
[ problem ] to provide a simple and efficient method for purifying tafluprost, which can be scaled up. [ solution ] the present invention relates to a method for purifying tafluprost, which comprises a step of purifying a crude product of tafluprost by silica gel column chromatography and collecting a fraction containing tafluprost by HPLC analysis. The present invention also relates to a method for producing tafluprost, which comprises the method for purifying tafluprost.
Description
Technical Field
The present invention relates to a novel purification process for tafluprost.
Background
Tafluprost is represented by the following formula:
the chemistry of whichIs named as (5Z) -7- (1R,2R,3R,5S) -2- [ (1E) -3, 3-difluoro-4-phenoxy-1-butenyl]-3, 5-dihydroxycyclopentyl]-isopropyl 5-heptenoate having a viscosity of 2440mPa · s at 25 ℃ and being a very viscous difluoroprostaglandin F2αAnd (3) derivatives. Tafluprost has an unstable chemical structure containing 2 double bonds, unsaturated fatty acid ester sites, and 4 asymmetric centers, and has a structure in which the hydroxyl group and hydrogen atom at the C15 position present in other prostaglandin derivatives are substituted with 2 fluorine atoms, and therefore, among prostaglandin derivatives, it has a remarkable specific property of high lipid solubility, and as prostaglandin derivatives, it has a property of being decomposed at high temperatures although it has high chemical stability. In addition, tafluprost has a potent ocular tension lowering effect and is used as an eye drop for the treatment of glaucoma and ocular hypertension (patent document 1). Patent document 1 describes difluoroprostaglandin F containing tafluprost2αA method for producing the derivative is also described in non-patent document 1.
The production method described in patent document 1 includes a Wittig reaction step, and thus it is difficult to avoid mixing of an α -chain trans isomer in the final product. Among the production methods described in patent document 1, a method of separation and purification by High Performance Liquid Chromatography (HPLC) for fractionation has been reported as a method of removing impurities including an α -chain trans isomer (patent document 2). However, tafluprost, and a carboxylic acid compound represented by the following formula (I) as a synthesis precursor thereof (hereinafter referred to as "tafluprost acid"):
all of them are liquid compounds having very high viscosity, and therefore, purification is difficult, and the purification method of tafluprost described in patent document 2 requires a high cost because a large amount of organic solvent is used, and it is also difficult to suppress the concentration of the residual organic solvent to be less than the concentration limit value of the residual solvent guideline for pharmaceuticals (non-patent document 2). The column of HPLC for fractionation is generally expensive and is generally used repeatedly, and therefore, there is a problem that the number of theoretical plates is reduced due to accumulated impurities, contamination of decomposition products, and deterioration of the column, and in order to reduce the risk caused by these problems, it is often necessary to perform washing using a large amount of organic solvent, and complicated validation of validity in relation to confirmation thereof, confirmation of the separation performance of the column, and the like, and therefore, the column is not practical as a method for producing a pharmaceutical.
On the other hand, a method of reducing the incorporation of impurities such as α -chain trans-isomer through an organic amine salt of tafluprost acid (patent documents 3 and 4) or a metal salt (patent document 5) has been reported, but with the addition of a salt formation step and a step of dissociating from the salt, there is an increased possibility of byproducts, dehydrates, other impurities, and the like, which are generated by dimerization or the like by condensation with organic amine or self-condensation. In addition, many organic amines and metals are also likely to have toxicity, mutagenicity, and the like, and particularly, they have a problem in safety when used as a purification method at a stage close to the final step of a pharmaceutical product.
Further, a method for producing tafluprost in which incorporation of an α -chain trans isomer is prevented by a macrolide ring formation step and a macrolide ring opening step has been reported (patent document 6). However, the above production method has a long production process and a low yield, and therefore has low practicability.
Documents of the prior art
Patent document
Patent document 1: european patent application publication No. 850926
Patent document 2: U.S. patent application publication No. 2014/0051882 specification
Patent document 3: international publication No. 2013/118058
Patent document 4: international publication No. 2016/090461
Patent document 5: chinese patent application publication No. 108299192 specification
Patent document 6: japanese patent laid-open publication No. 2015-36382
Non-patent document
Non-patent document 1: tetrahedron lett, 2004,45,1527-
Non-patent document 2: pharmaceutical examination No. 307, Housheng province drug safety administration review management class length notice (average 10 years, 3 months and 30 days), guidelines on residual solvents of drugs
Disclosure of Invention
Problems to be solved by the invention
The purpose of the present invention is to provide a method for purifying tafluprost, which can purify tafluprost, which is a liquid compound having a very high viscosity, simply and at low cost to such a degree of purity that it can be provided directly as a pharmaceutical drug substance, and which can also be scaled up (scale up).
Means for solving the problems
The present inventors have conducted extensive studies to solve the above problems and as a result have found that: in the method for producing tafluprost, tafluprost having high purity can be obtained by a purification method including a step of purifying a crude product of tafluprost obtained in the step of esterifying tafluprost acid by silica gel column chromatography and collecting a fraction containing tafluprost by HPLC analysis (hereinafter, also referred to as "the purification method of the present invention"). The present invention has been completed by carrying out a purification method comprising a step of concentrating a fraction containing tafluprost collected by HPLC analysis under reduced pressure at 10 to 55 ℃, a step of dissolving the residue in a solvent and filtering the solution, and a step of distilling off the solvent from the filtrate under reduced pressure at 10 to 55 ℃ and a final ultimate vacuum degree of 5torr or less (hereinafter, the purification method comprising all the steps may be referred to as "the purification method of the present invention").
Namely, the present invention is as follows.
[1] A method of purifying tafluprost, comprising: a step of purifying the crude product of tafluprost by silica gel column chromatography and collecting a fraction containing tafluprost by HPLC analysis.
[2] The method for purifying tafluprost according to the above [1], further comprising: concentrating under reduced pressure the fraction containing tafluprost analyzed and collected by HPLC at 10-55 deg.C; then dissolving the residue in a solvent and filtering; and distilling off the solvent from the filtrate under reduced pressure at 10-55 ℃ and a final ultimate vacuum degree of 5torr or less.
[3] The purification method according to the above [1] or [2], wherein the silica gel used for the silica gel column chromatography has a particle size (d50) of 20 to 70 μm.
[4] The purification method according to any one of the above [1] to [3], wherein the silica gel used for the silica gel column chromatography is spherical.
[5] The purification method according to any one of the above [1] to [4], wherein the eluent for the silica gel column chromatography is a mixed solvent of n-hexane and a polar solvent, or a mixed solvent of n-heptane and a polar solvent.
[6] The purification method according to the above [5], wherein the eluent is a mixed solvent of n-hexane and a polar solvent.
[7] The purification process according to the above [5] or [6], wherein the polar solvent is ethyl acetate, t-butyl methyl ether, 2-propanol, or ethanol.
[8] The purification method according to any one of the above [1] to [7], wherein the HPLC analysis is a reversed-phase HPLC analysis.
[9] The purification method according to any one of the above [1] to [8], wherein the component is a component containing 98% or more of tafluprost.
[10] The purification method according to any one of the above [2] to [9], wherein the filtration is performed using a filter having a pore size of 0.5 μm or less.
[11] The purification method according to any one of the above [2] to [10], wherein the solvent for dissolving the residue is ethyl acetate, tert-butyl methyl ether, 2-propanol or ethanol, or a mixed solvent of ethyl acetate, tert-butyl methyl ether, 2-propanol or ethanol and a nonpolar solvent.
[12] The purification process according to the above [11], wherein the solvent for dissolving the residue is ethyl acetate or a mixed solvent of ethyl acetate and a nonpolar solvent.
[13] The purification method according to the above [11] or [12], wherein the nonpolar solvent is n-hexane or n-heptane.
[14] The purification method according to any one of the above [2] to [13], wherein the final ultimate vacuum degree is 1torr or less.
[15] The purification method according to any one of the above [2] to [14], wherein the residual solvent concentration of n-hexane after the step of distilling off the solvent of the filtrate is 290ppm or less, and the residual solvent concentrations of n-heptane, ethyl acetate, tert-butyl methyl ether, 2-propanol or ethanol are 5000ppm or less, respectively.
[16] A method for producing tafluprost, which comprises subjecting a crude product of tafluprost to the purification method according to any one of the above [1] to [15 ].
[17] Tafluprost obtained by the production method according to [16 ].
[18] A pharmaceutical product comprising the tafluprost of [17] as an active ingredient.
[19] A pharmaceutical product for preventing or treating an ocular disease, which comprises the tafluprost of [17] as an active ingredient.
[20] The pharmaceutical product according to the above [19], wherein the ocular disease is glaucoma or ocular hypertension.
ADVANTAGEOUS EFFECTS OF INVENTION
According to the purification method of the present invention, when a crude product of tafluprost is separated and purified by silica gel column chromatography in the final step of production of tafluprost, contamination of impurities can be minimized by collecting a fraction containing tafluprost by HPLC analysis. Further, by distilling off the solvent with time under reduced pressure conditions of low temperature and high vacuum degree, the concentration of the residual organic solvent can be suppressed to a value not more than the concentration limit value of the residual solvent rule of the pharmaceutical product, and the decomposition of tafluprost which is unstable at high temperature can be suppressed. Furthermore, since the fine powder of silica gel, airborne particles in the air, and bacteria can be removed by incorporating a filter filtration step in the middle, it is possible to easily and efficiently provide high-purity tafluprost that can be used as a drug substance of a pharmaceutical product directly after the solvent is distilled off. The purification method of the present invention can be widely applied to a crude product of tafluprost produced by a known method, and can withstand scale-up.
Detailed Description
Embodiments of the present invention will be described in detail below.
[ definition of terms ]
The terms used in the present specification have the following meanings.
In the present specification, as a column used for the "silica gel column chromatography", either a normal pressure column or a flash column can be used.
The "silica gel column chromatography" in the present specification is a column chromatography of a positive phase system.
In the present specification, the term "crude product of tafluprost" refers to a product after post-treatment of a reaction in a final step in a known production method of tafluprost and before purification. Specifically, for example, as shown in examples described later, a product before purification of a final esterification reaction in the method for producing tafluprost described in patent document 1, and the like can be given.
In the present specification, the term "impurities" includes all substances other than tafluprost, such as residual reaction reagents, residual raw material compounds, reaction by-products, and decomposition products of tafluprost, which are contained in the crude product of tafluprost, as well as residual organic solvents, residues derived from fillers, and bacteria.
In the present specification, "HPLC analysis" refers to confirmation of the presence or absence and content ratio of tafluprost in each fraction by high performance liquid chromatography (high performance liquid chromatography) for analysis when a crude product of tafluprost is separated and purified by silica gel column chromatography.
In the present specification, "filtration" refers to filter filtration. The filtration is performed for the purpose of removing fine powder of a column packing (silica gel), floating particles in the air, bacteria, and the like.
In the present specification, the "polar solvent" refers to a solvent having a large dielectric constant. Specific examples of the polar solvent include esters such as ethyl acetate and propyl acetate, ethers such as diethyl ether, tert-butyl methyl ether and tetrahydrofuran, and alcohols such as 2-propanol and ethanol. Among them, ethyl acetate, t-butyl methyl ether, 2-propanol or ethanol is preferable.
In the present specification, the term "nonpolar solvent" refers to a solvent having a small dielectric constant. Specific examples of the nonpolar solvent include chain hydrocarbons such as n-hexane and n-heptane. Among them, n-hexane is preferable.
In the present specification, "outside temperature" refers to the temperature outside the reaction vessel or the concentration vessel, and is usually the outside air temperature or the temperature of a water bath or a hot water bath.
In the present specification, the "concentration limit value of the criterion for the residual solvent of a pharmaceutical product" is a value which is studied as one of the subjects of the international conference on approval review of pharmaceutical products in the japanese and american EU three parties (ICH) and which defines the allowable amount of the residual solvent in the pharmaceutical product for the safety of patients, and refers to a limit value which can be tolerated in the toxicology of the residual solvent. Specific examples of the concentration limit value of the residual solvent in the pharmaceutical are, for example, 290ppm for n-hexane and 5000ppm for n-heptane, ethyl acetate, tert-butyl methyl ether, 2-propanol or ethanol, as described in non-patent document 2.
[ purification method of the present invention ]
The purification method of the present invention is characterized by comprising a step of purifying a crude tafluprost product by silica gel column chromatography and collecting a fraction containing tafluprost by HPLC analysis (step 1). In addition, in order to suppress the concentration of the residual organic solvent to be less than or equal to the limit value of the concentration of the residual solvent standard of the pharmaceutical product, the purification method of the present invention is characterized by comprising, in addition to the step 1, a concentration step (step 2) of reducing the pressure at 10 to 55 ℃, a step (step 3) of dissolving the residue in the solvent and filtering the solution, and a step (step 4) of distilling off the solvent of the filtrate under reduced pressure at 10 to 55 ℃ and a final limit vacuum of 5torr or less.
(step 1)
This step is a step of purifying the fraction by silica gel column chromatography and collecting the fraction containing tafluprost by HPLC analysis.
The filler used for silica gel column chromatography is not particularly limited as long as it is silica gel that can be used in a normal phase column. The silica gel may be in the form of a powder or a sphere, and a sphere is more preferable. The particle diameter (d50) of the silica gel is not particularly limited, but is preferably 20 to 70 μm, more preferably 40 to 65 μm, and particularly preferably 45 to 60 μm. The particle diameter (d50) is a median diameter of a particle size distribution obtained by measuring a particle size distribution by laser diffraction scattering method and preparing the particle size distribution on a volume basis.
The eluent used for the silica gel column chromatography is not particularly limited as long as it is a solvent capable of separating tafluprost from impurities in a crude product of tafluprost, and a mixed solvent of n-hexane and a polar solvent or a mixed solvent of n-heptane and a polar solvent is preferred, and a mixed solvent of n-hexane and a polar solvent is more preferred. Here, the polar solvent is selected from ethyl acetate, t-butyl methyl ether, 2-propanol and ethanol, and among them, 2-propanol or ethanol is preferable. The mixing ratio (volume ratio) of n-hexane to the polar solvent or n-heptane to the polar solvent can be appropriately set depending on the kind, shape and/or particle size of the filler used. Preferable specific examples of the eluent include ethyl acetate, t-butyl methyl ether, a mixed solvent of 2-propanol or ethanol and a nonpolar solvent (preferably n-hexane or n-heptane), more preferably a mixed solvent of 2-propanol or ethanol and a nonpolar solvent (preferably n-hexane or n-heptane), and particularly preferably a mixed solvent of ethanol and n-hexane. The mixing ratio (volume ratio) when a mixed solvent is used as the eluent is not particularly limited, but from the viewpoint of controlling the residual solvent concentration to be equal to or less than a reference value, a mixed solvent of ethanol and n-hexane is preferably used in a range of 10: 90-1: 99 mixing ethanol: the solvent derived from n-hexane is more preferably a solvent of 6: 94-2: 98, preferably 5: 95-3: 97, particularly preferably in a ratio of 4: 96 to obtain a mixed solvent.
When the presence or absence of tafluprost in the separated fractions was confirmed by silica gel column chromatography, HPLC for analysis was used. As the HPLC, both normal phase HPLC and reverse phase HPLC may be used, but reverse phase HPLC excellent in separation efficiency of impurities, detection sensitivity, quantitativity, and the like is more preferable. Specific examples of the column and analysis conditions used in the HPLC analysis include the conditions described in the following examples, but are not limited thereto.
In general, in the case of purification by silica gel column chromatography, the presence or absence of a target substance in the separated fractions was confirmed by TLC (thin layer chromatography) (see basic procedure I (4 th edition) of experimental chemistry lecture 1, published in 2 years, 11 months, 5 days, pillared 5/2/3 column chromatography, p.293-296), but it was found that HPLC analysis was significantly superior in the detection sensitivity of the fractions containing tafluprost and impurities, compared to conventional TLC analysis, in the purification of a crude tafluprost product.
Silica gel column chromatography was performed on a plurality of batches of the synthesized crude tafluprost product, and the elution pattern of impurities was analyzed by HPLC analysis, and as a result, it was confirmed that the elution pattern of impurities was always stable. As can be seen from consideration of the impurity elution pattern, it is preferable to collect a continuous fraction having an HPLC area percentage of tafluprost of 97% or more, and it is particularly preferable to collect 98% or more of the continuous fraction for each fraction.
(step 2)
The step is a step of collecting a fraction containing tafluprost which is analyzed and confirmed by HPLC, and concentrating the collected fraction under reduced pressure at 10 to 50 ℃.
The external temperature (temperature of water bath or hot water bath) when the fraction containing tafluprost confirmed by HPLC analysis is collected and concentrated under reduced pressure is preferably 10 to 55 ℃, more preferably 15 to 50 ℃, and particularly preferably 20 to 45 ℃. As shown in the test examples described below, it was confirmed that tafluprost gradually decomposes at a temperature of 60 ℃ or higher with the passage of time, and from this point of view, it is also preferable to perform concentration under reduced pressure at the above-mentioned temperature or to distill off the solvent.
(step 3)
This step is a step of dissolving the residue obtained in the step 2 in a solvent and filtering the solution. Tafluprost is very viscous and therefore it is difficult to perform sterile filtration after complete distillation of the solvent. Therefore, the purification method of the present invention is characterized by including a filtration step after step 2.
The solvent used for dissolving the residue obtained in step 2 may be the same solvent as the eluent used in the silica gel column chromatography in step 1, preferably a solvent having a relatively low boiling point and sufficiently dissolving tafluprost, or a mixed solvent with a nonpolar solvent having an azeotropic composition. Specifically, ethyl acetate, tert-butyl methyl ether, 2-propanol or ethanol is preferable, or a mixed solvent of ethyl acetate, tert-butyl methyl ether, 2-propanol or ethanol and a nonpolar solvent (preferably n-hexane or n-heptane) is preferable, ethyl acetate is more preferable, or a mixed solvent of ethyl acetate and a nonpolar solvent (preferably n-hexane or n-heptane) is more preferable, and a mixed solvent of ethyl acetate and n-hexane is particularly preferable. The mixing ratio (volume ratio) when the mixed solvent is used is not particularly limited, and from the viewpoint of controlling the residual solvent concentration to be equal to or less than the reference value, it is particularly preferable to use a mixed solvent of ethyl acetate and n-hexane in an amount of 10: 1-1: 10. preferably 4: 1-1: 4. more preferably 2: 1-1: 2, mixing ethyl acetate: n-hexane.
The filter used in the filtration in this step is not particularly limited as long as it is capable of removing fine powder of the filler (silica gel), floating particles in the air, and the like without swelling and dissolving by the solvent, and examples thereof include a glass fiber filter, a polypropylene filter, a nylon filter, a fluororesin filter, and the like, and a fluororesin filter such as polyvinylidene fluoride (PVDF) and Polytetrafluoroethylene (PTFE) is preferable, and a Polytetrafluoroethylene (PTFE) filter is particularly preferable.
The pore size of the filter is usually 0.5 μm or less, preferably 0.25 μm or less, and particularly preferably 0.22 μm or less when sterilization is also included.
(step 4)
The solvent of the filtrate obtained in the step 3 is distilled off at 10 to 55 ℃ under reduced pressure with a final ultimate vacuum degree of 5torr or less.
Tafluprost is very viscous and therefore it is necessary to maximize the surface area over which the solvent evaporates and to take time to slowly distill off the filtrate while avoiding bumping. Examples of the vacuum concentration apparatus for achieving the above object include a rotary evaporator, a centrifugal evaporator, and a high vacuum thin film evaporator.
As described above, the external temperature (temperature of water bath or hot water bath) when the solvent is distilled off under reduced pressure is preferably 10 to 55 ℃, more preferably 15 to 50 ℃, and particularly preferably 20 to 45 ℃ in view of gradual decomposition of tafluprost at a temperature of 60 ℃ or higher over time.
The degree of reduced pressure at the time of distilling off the solvent is preferably controlled so that the final ultimate vacuum degree becomes 5torr or less (preferably 3torr or less, more preferably 1torr or less, particularly preferably 0.5torr or less) because the surface area of the solvent to be evaporated is as large as possible and the time required for bumping is gradually increased while avoiding bumping. When the reduced pressure is released, it is preferable to return to normal pressure using air passed through a filter in order to prevent the entry of floating particles and bacteria in the air.
The time for distilling off the solvent is preferably 10 to 70 hours, more preferably 15 to 60 hours, and particularly preferably 20 to 60 hours.
By using the purification method of the present invention, the concentration of the residual organic solvent can be suppressed to a value not more than the concentration limit value of the residual solvent guideline (non-patent document 2) for pharmaceuticals, and "residual solvent" as described in the guideline does not contribute to the treatment, and therefore, the total residual solvent should be reduced to a level not more than a level that can meet the product standard, GMP, or other quality standards. ", it is possible to stably produce high-quality tafluprost which can further meet strict various quality standards.
As a solvent for dissolving the eluent and the residue used in the silica gel column chromatography, preferred are: the residual solvent concentrations of ethyl acetate, t-butyl methyl ether, 2-propanol, ethanol, or n-heptane, which are exemplified as preferred solvents, can be produced more preferably by controlling the residual solvent concentrations to 1000ppm or less, particularly preferably to 100ppm or less, and further preferably: the residual solvent concentration of n-hexane can be controlled more preferably to 200ppm or less, particularly preferably to 20ppm or less. The concentration of the residual solvent can be measured by a method such as Gas Chromatography (GC).
The present invention also includes a method for producing tafluprost, in which a crude product of tafluprost produced by a known method is subjected to the step of the purification method of the present invention (the purification method including the above-described steps 1to 4). As a known production method of tafluprost, there are some reports (for example, U.S. patent application publication No. 2014/0046086; J.org.chem.2016,81,10832-844; Molecules,2017,22,217, 1-16; org.Lett.2020,22,2991-2994, etc.) in addition to the aforementioned patent document 1 and non-patent document 1, and these can be included in the present invention by combining with the purification method of the present invention.
Specific examples of the crude product of tafluprost used in the present invention include, for example, a crude product of tafluprost obtained by deprotection reaction of tafluprost protected with a hydroxyl group or the like, a crude product of tafluprost obtained by esterification of a salt of tafluprost acid, a crude product of tafluprost obtained by esterification of tafluprost acid, and the like. Among them, a crude product of tafluoroprostane obtained by esterification of tafluoroprostane acid can be suitably used.
Specific features of the purification method of the present invention include the following.
(A) When a crude product of tafluprost is separated and purified by silica gel column chromatography, components containing tafluprost are collected by HPLC analysis (preferably reverse phase HPLC analysis), whereby contamination of impurities can be suppressed to a minimum.
(B) By removing the solvent by distillation over a long period of time under reduced pressure conditions of low temperature and high vacuum, the decomposition of tafluprost which is unstable at high temperature can be suppressed, and the concentration of the residual organic solvent can be suppressed to a value equal to or lower than the concentration limit of the residual solvent rule of the pharmaceutical product.
(C) By incorporating a filter filtration step in the middle, it is possible to provide high-purity tafluprost that can be used as a drug substance of a pharmaceutical as it is after the solvent is distilled off.
(D) The purification method of the present invention can be applied to a crude product of tafluprost obtained by any of known methods for producing tafluprost, and can be easily scaled up, so that a simple and efficient purification method can be provided.
The purification method of the present invention may be carried out for the purpose of improving the purity of tafluprost as described in (a) above, and may include only step 1, or may be combined with steps 2to 4, if necessary, in step 1.
Examples
The present invention will be described in detail below with reference to reference examples, examples and test examples, but the present invention is not limited to these examples.
% represents mol% in the yield, and% represents mass% in the rest unless otherwise specified. The ratio shown in the mixed solvent represents a volume ratio unless otherwise specified. The room temperature is 15 to 30 ℃ unless otherwise specified. The following are provided1The H-NMR value was measured by using ECP400(400MHz) manufactured by Nippon electronics Co., Ltd. The HPLC apparatus used Shimadzu LC-10ADvp or LC-10A. The GC apparatus used Shimadzu GC-2014 ATF.
Reference example 1: synthesis of tafluprost acid
Tetrahydrofuran (1200g) was added to and dissolved in (1S,5R,6R,7R) -6- [ (1E) -3, 3-difluoro-4-phenoxy-1-butenyl ] -7-hydroxy-2-oxabicyclo [3.3.0] octan-3-one (280g) under a nitrogen atmosphere, and diisobutylaluminum hydride (1M in toluene) (2160mL) was added dropwise at-70 ℃. After completion of the dropwise addition, the mixture was stirred for 30 minutes, 1N hydrochloric acid was added thereto, and extraction was performed with ethyl acetate. The organic layers were combined, washed with water, and the filtrate was concentrated under reduced pressure to obtain a reduced sample (284 g). Tetrahydrofuran (5030g) was added to 4-carboxybutyltriphenylphosphonium bromide (1523g) under a nitrogen atmosphere, and a solution of sodium bis (trimethylsilyl) amide (1M tetrahydrofuran solution) (6684mL) was added dropwise and stirred for 1 hour or more. The above-mentioned reducing agent (286g) dissolved in tetrahydrofuran (970g) was added dropwise at 0 ℃ and stirred for 3 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The aqueous layer was acidified, extracted with ethyl acetate, concentrated under reduced pressure, and then insoluble materials were filtered off, followed by purification by silica gel column chromatography (hexane/ethyl acetate 1/1 to 1/3) to obtain tafluprost acid (222 g).
1H NMR(CDCl3)δ1.60(m,1H),1.67(m,2H),1.84(m,1H),2.02-2.16(m,4H),2.25-2.35(m,3H),2.47(m,1H),4.03(m,1H),4.18(m,3H),5.35-5.42(m,2H),5.80(m,1H),6.10(m,1H),6.91(m,2H),7.00(m,1H),7.30(m,2H).
Reference example 2: synthesis of crude Tafluprost product
In a 5L flask, under a nitrogen atmosphere, tafluprost acid (120g) obtained in reference example 1 was charged and dissolved in acetone (600mL) with stirring. After cooling to 5 ℃ and dropping 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU) (160mL) while maintaining the temperature at or below 5 ℃ and dropping 2-iodopropane (146mL) while maintaining the temperature at or below 5 ℃, the mixture was stirred at 30 ℃ until the conversion of the reaction became 95% or more. To the reaction mixture were added ethyl acetate (1800mL) and a 5% aqueous citric acid solution (900mL) and the mixture was separated, and the organic layer was washed with a 5% aqueous citric acid solution (900mL, 1 time), a 5% aqueous sodium bicarbonate solution (900mL, 2 times), and purified water (900mL, 1 time). The solvent was distilled off under reduced pressure at 40 ℃ or lower, whereby a crude product of tafluprost (132g, yield 100%; HPLC purity: 95.5%, content of. alpha. -chain trans-isomer: 0.73%) was obtained.
Example 1
Step 1 a column was filled with a slurry prepared from silica gel (AGC-SITECH co., LTD, m.s. gel D50-120A, particle size (D50): 50 μm, spherical, 50g) and n-hexane/ethanol 96/4, and the crude tafluprost (1g) obtained in reference example 2 was dissolved in n-hexane/ethyl acetate 1/1 and packed into the column and eluted with n-hexane/ethanol 96/4. The fractions were analyzed by HPLC and fractions containing tafluprost were collected. As the component containing tafluprost, at least a component in which the area percentage of tafluprost is 98% or more (calculated by subtracting the solvent peak) is collected.
(step 2) the collected fraction containing tafluprost is concentrated under reduced pressure at 35 ℃ to 40 ℃.
(step 3) the residue was dissolved in n-hexane/ethyl acetate 3/2, filtered through a membrane filter (pore size: 0.2 μm), and washed with n-hexane/ethyl acetate 3/2.
(step 4) the solvent in the filtrate was distilled off overnight under reduced pressure at 35 to 40 ℃ and a final ultimate vacuum degree of 1torr or less, whereby tafluprost (colorless to pale yellow viscous liquid, yield: 82%, HPLC purity: 99.5%, content of. alpha. -chain trans-isomer: 0.25%) was obtained.
The residual solvent concentration of the obtained tafluprost was analyzed by GC, and as a result, n-hexane was 0ppm, ethyl acetate was 0ppm, and ethanol was 0 ppm.
1H NMR(CDCl3)δ1.22(d,J=6.2Hz,3H),1.22(d,J=6.2Hz,3H),1.58-1.63(m,1H),1.63-1.69(m,2H),1.84(d,J=14.7Hz,1H),2.02-2.08(m,1H),2.10-2.16(m,3H),2.25(t,J=7.3Hz,1H),2.26(t,J=7.1Hz,1H),2.30-2.35(m,1H),2.46-2.49(m,2H),2.61-2.63(m,1H),4.02-4.03(m,1H),4.18-4.21(m,3H),5.00(heptet,J=6.2Hz,1H),5.35-5.42(m,2H),5.80(dt,J=15.8,11.2Hz,1H),6.10(dd,J=15.8,8.8Hz,1H),6.91(d,J=8.8Hz,2H),7.00(t,J=7.3Hz,1H),7.30(dd,J=8.8,7.3Hz,2H);
19F NMR(CDCl3)δ-102.8(dq,2JFF=255.6Hz),-103.6(dq,2JFF=255.6Hz).
< conditions for HPLC (reverse phase) analysis >
Column: YMC-Pack ODS-AM (5 μm, 6.0X 150mm)
Temperature: at room temperature
Flow rate: 1 mL/min
Detection wavelength: 220nm
Eluent: (solution A) 1% triethylamine-phosphate buffer (pH6.3),
(solution B) acetonitrile
Gradient conditions: A/B50/50 (0-45 min), A/B25/75 (45-70 min)
< GC analysis conditions >
Column: g-column G300(1.2mm I.D., 40m)
Column temperature: 50 deg.C
And (3) detection: hydrogen flame ionization detector
Carrier gas: helium
Injector temperature: 160 deg.C
Detector temperature: 160 deg.C
Examples 2to 6
In order to examine the influence of the type of silica used for silica gel column chromatography on the purity and yield of tafluprost, the following experiment was performed in the same manner as in example 1.
The results of silica gel column chromatography using crude tafluprost (1 g; HPLC purity: 95.5%) and silica gel (50g) are shown in Table 1 below. Reverse phase HPLC analysis was performed under the same conditions as described above.
[ Table 1]
Comparative example 1
Silica gel column chromatography was performed using the crude tafluprost (1 g; HPLC purity: 95.5%), silica gel (50g) used in example 2, and an eluent. As a result of collecting a fraction containing only tafluprost by visual observation in the same manner as in example 1 except that the fractionated fractions were analyzed by TLC instead of HPLC, the HPLC purity of the obtained tafluprost was 97.3%, which did not reach the quality level (limit value: 98%) required for a purified product as a pharmaceutical product.
When the particle size (d50) of the silica gel used was 65 μm or less, tafluprost having a purity of more than 98% was obtained in all of examples 1to 6, although the shape was different. Among them, it was found that when spherical silica gel is used, tafluprost having particularly high purity can be obtained in high yield.
Example 7 (scale-up study)
(step 1)
In the same manner as in step 1 of example 1, a slurry prepared from silica gel (AGC-SITECH co., LTD, m.s.gel D50-120A, particle size (D50): 50 μm, spherical, 6.0kg) and n-hexane/ethanol 96/4 was packed in a column, and the crude tafluprost (120g) obtained in reference example 2 was dissolved in n-hexane/ethyl acetate 1/1, packed in the column, and eluted with n-hexane/ethanol 96/4. The fractions were analyzed by HPLC and fractions containing tafluprost were collected. As the component containing tafluprost, at least a component in which the area percentage of tafluprost is 98% or more (calculated by subtracting the solvent peak) is collected.
(Steps 2to 4)
The fraction containing tafluprost collected in step 1 is concentrated under reduced pressure at 29 to 35 ℃ (step 2).
The residue was dissolved in n-hexane/ethyl acetate 3/2, filtered through a membrane filter (pore size: 0.2 μm), and washed with n-hexane/ethyl acetate 3/2 (step 3).
The solvent in the filtrate was distilled off under reduced pressure at 32 to 36 ℃ and a final ultimate vacuum degree of 0.30torr for 26 hours (step 4), whereby tafluprost (colorless to pale yellow viscous liquid, yield: 86%, HPLC purity: 99.7%, content of. alpha. -chain trans-isomer: 0.24%, content of microorganism: 10cfu/0.1g or less) was obtained.
The residual solvent concentration of the obtained tafluprost was analyzed by GC, and as a result, n-hexane was 0ppm, ethyl acetate was 0ppm, and ethanol was 0 ppm.
Example 8
The fraction containing tafluprost purified and collected in the same manner as in step 1 of example 7 was concentrated under reduced pressure in the same manner as in step 2 of example 7.
The obtained residue was dissolved in ethyl acetate, filtered through a membrane filter (pore size: 0.2 μm), and washed with ethyl acetate (step 3).
The solvent in the filtrate was distilled off under reduced pressure at 23 to 37 ℃ and a final ultimate vacuum degree of 0.26torr for 27 hours (step 4), whereby tafluprost (colorless to pale yellow viscous liquid, yield: 85%, HPLC purity: 99.7%, content of. alpha. -chain trans-isomer: 0.27%, content of microorganism: 10cfu/0.1g or less) was obtained.
The residual solvent concentration of the obtained tafluprost was analyzed by GC, and as a result, n-hexane was 0ppm, ethyl acetate was 0ppm, and ethanol was 0 ppm.
Example 9
The fraction containing tafluprost purified and collected in the same manner as in step 1 of example 7 was concentrated under reduced pressure in the same manner as in step 2 of example 7, and the residue was dissolved in n-hexane/ethyl acetate 3/2, filtered through a membrane filter (pore size: 0.2 μm), and washed with n-hexane/ethyl acetate 3/2 (step 3).
The solvent in the filtrate was distilled off under reduced pressure at 20 to 36 ℃ and a final ultimate vacuum degree of 2.6torr for 3 hours (step 4), whereby tafluprost (colorless to pale yellow viscous liquid, yield: 75%, HPLC purity: 99.4%, content of. alpha. -chain trans-isomer: 0.30%, content of microorganism: 10cfu/0.1g or less) was obtained.
The residual solvent concentration of the obtained tafluprost was analyzed by GC, and as a result, n-hexane was 36ppm, ethyl acetate was 4803ppm, and ethanol was 66 ppm.
Example 10
The fraction containing tafluprost purified and collected in the same manner as in step 1 of example 7 was concentrated under reduced pressure in the same manner as in step 2 of example 7, and the residue was dissolved in n-hexane/ethyl acetate 3/2, filtered through a membrane filter (pore size: 0.2 μm), and washed with n-hexane/ethyl acetate 3/2 (step 3).
The solvent in the filtrate was distilled off under reduced pressure at 34 to 37 ℃ and a final ultimate vacuum degree of 2.1torr for 5 hours (step 4), whereby tafluprost (colorless to pale yellow viscous liquid, yield: 78%, HPLC purity: 99.5%, content of. alpha. -chain trans-isomer: 0.32%, content of microorganism: 10cfu/0.1g or less) was obtained.
The residual solvent concentration of tafluprost obtained was analyzed by GC, and as a result, n-hexane was 2ppm, ethyl acetate was 785ppm, and ethanol was 0 ppm.
Example 11
The fraction containing tafluprost purified and collected in the same manner as in step 1 of example 7 was concentrated under reduced pressure in the same manner as in step 2 of example 7, and the residue was dissolved in n-hexane/ethyl acetate 3/2, filtered through a membrane filter (pore size: 0.2 μm), and washed with n-hexane/ethyl acetate 3/2 (step 3).
The solvent in the filtrate was distilled off under reduced pressure at 32 to 36 ℃ and a final ultimate vacuum degree of 0.92torr for 8 hours (step 4), whereby tafluprost (colorless to pale yellow viscous liquid, yield: 82%, HPLC purity: 99.6%, content of. alpha. -chain trans-isomer: 0.26%, content of microorganism: 10cfu/0.1g or less) was obtained.
The residual solvent concentration of the obtained tafluprost was analyzed by GC, and as a result, n-hexane was 0ppm, ethyl acetate was 86ppm, and ethanol was 0 ppm.
Example 12
The fraction containing tafluprost purified and collected in the same manner as in step 1 of example 7 was concentrated under reduced pressure in the same manner as in step 2 of example 7, and the residue was dissolved in n-hexane/ethyl acetate 3/2, filtered through a membrane filter (pore size: 0.2 μm), and washed with n-hexane/ethyl acetate 3/2 (step 3).
The solvent in the filtrate was distilled off under reduced pressure at 35 ℃ to 39 ℃ and a final ultimate vacuum degree of 0.09torr for 50 hours (step 4), whereby tafluprost (colorless to pale yellow viscous liquid, yield: 80%, HPLC purity: 99.5%, content of. alpha. -chain trans-isomer: 0.26%, content of microorganism: 10cfu/0.1g or less) was obtained.
The residual solvent concentration of tafluprost obtained was analyzed by GC, and as a result, n-hexane was 0ppm, ethyl acetate was 0ppm and ethanol was 0 ppm.
Example 13
The fraction containing tafluprost purified and collected in the same manner as in step 1 of example 7 was concentrated under reduced pressure in the same manner as in step 2 of example 7, and the residue was dissolved in n-hexane/ethyl acetate 3/2, filtered through a membrane filter (pore size: 0.2 μm), and washed with n-hexane/ethyl acetate 3/2 (step 3).
The solvent in the filtrate was distilled off under reduced pressure at 36 to 45 ℃ and a final ultimate vacuum degree of 0.24torr for 60 hours (step 4), whereby tafluprost (colorless to pale yellow viscous liquid, yield: 79%, HPLC purity: 99.5%, content of. alpha. -chain trans-isomer: 0.26%, content of microorganism: 10cfu/0.1g or less) was obtained.
The residual solvent concentration of the obtained tafluprost was analyzed by GC, and as a result, n-hexane was 0ppm, ethyl acetate was 0ppm, and ethanol was 0 ppm.
The conditions for distilling off the solvent, the yield and purity of tafluprost, the content of α -chain trans-isomer, and the residual solvent concentration in examples 7 to 13 are shown in table 2 below.
[ Table 2]
As is clear from table 2, in each of examples 7 to 13, tafluprost was obtained with good purity and high yield, and the residual organic solvent concentration could be suppressed to be less than the concentration limit value of the residual solvent rule of the pharmaceutical products. On the other hand, it was confirmed that: in the comparative example in which concentration was carried out under reduced pressure at a final ultimate vacuum of 8torr, the residual organic solvent concentration exceeded the concentration limit value of the residual solvent criterion for the pharmaceutical.
Test examples
Study of the thermal stability of Tafluprost
Approximately 120mg of tafluprost obtained in example 1 was weighed out into glass containers, stored in a thermostatic chamber at 40 ℃ and quantified by reverse phase HPLC analysis, and the change in the content of tafluprost over time was examined. Similarly, approximately 20mg of tafluprost was measured in glass containers, stored in a thermostatic bath at 60 ℃ or 80 ℃, and the change in tafluprost content over time was examined.
< conditions for HPLC (reverse phase) analysis >
Column: YMC-Pack ProC18 AS-303(5 μm, 4.6X 250mm)
Temperature: 50 deg.C
Flow rate: 1 mL/min
Detection wavelength: 220nm
Eluent: (solution A) 10mmol/L phosphate (sodium) buffer solution (pH6.9),
(solution B) acetonitrile
Gradient conditions: A/B50/50 (0-45 min), A/B25/75 (45-70 min)
The results of examining the change with time of the content of tafluprost at each temperature are shown in tables 3to 5 below.
[ Table 3]
Stability of Tafluprost at 40 ℃
Time (moon) | 0 | 3 | 6 |
Content of Tafluprost (%) | 101.3 | 99.8 | 99.4 |
[ Table 4]
Stability of Tafluprost at 60 ℃
Time (sky) | 0 | 3 | 7 | 14 |
Content of Tafluprost (%) | 99.0 | 98.9 | 98.5 | 95.4 |
[ Table 5]
Stability of Tafluprost at 80 ℃
Time (day)) | 0 | 1 | 3 | 7 |
Content of Tafluprost (%) | 99.5 | 99.1 | 94.4 | 86.7 |
From the results of tables 3to 5, it was confirmed that: tafluprost slowly decomposes over time, particularly significantly decomposes at 80 ℃ at a temperature of 60 ℃ or higher even during storage for a period of about several days to 2 weeks, but it is found that tafluprost stably exists at 40 ℃ even after 6 months.
From the above results, it can be seen that: in the purification method of the present invention, the concentration under reduced pressure and the distillation removal of the solvent are performed at a temperature of 55 ℃ or lower (particularly preferably 45 ℃ or lower), whereby the contamination of impurities (analogous substances) derived from the decomposition of tafluprost can be suppressed.
Industrial applicability
According to the purification method of the present invention, when a crude product of tafluprost is separated and purified by silica gel column chromatography in the final step in the production of tafluprost, the contamination of impurities can be minimized by collecting fractions containing tafluprost by HPLC analysis. Further, by distilling off the solvent with time under reduced pressure conditions of low temperature and high vacuum degree, the concentration of the residual organic solvent can be suppressed to be not more than the concentration limit value of the residual solvent rule of the pharmaceutical product, and the decomposition of tafluprost which is unstable at high temperature can be suppressed. Further, since the fine powder of silica gel, airborne particles in the air, and bacteria can be removed by incorporating a filter filtration step in the middle of the process, there is an advantage that high-purity tafluprost which can be used as a drug substance of a pharmaceutical can be easily and efficiently provided after the solvent is distilled off. The purification method of the present invention can be widely applied to a crude product of tafluprost produced by a known method, and is a highly versatile method that can also withstand scale-up.
Claims (20)
1. A method of purifying tafluprost, comprising: a step of purifying the crude product of tafluprost by silica gel column chromatography and collecting a fraction containing tafluprost by HPLC analysis.
2. The method of purifying tafluprost according to claim 1, further comprising: concentrating under reduced pressure the fraction containing tafluprost analyzed and collected by HPLC at 10-55 deg.C; then dissolving the residue in a solvent and filtering; and distilling off the solvent from the filtrate under reduced pressure at 10-55 ℃ and a final ultimate vacuum degree of 5torr or less.
3. The purification method according to claim 1 or 2, wherein the silica gel used for the silica gel column chromatography has a particle size (d50) of 20 to 70 μm.
4. The purification method according to any one of claims 1to 3, wherein the silica gel used in the silica gel column chromatography is spherical.
5. The purification method according to any one of claims 1to 4, wherein the eluent for the silica gel column chromatography is a mixed solvent of n-hexane and a polar solvent, or a mixed solvent of n-heptane and a polar solvent.
6. The purification method according to claim 5, wherein the eluent is a mixed solvent of n-hexane and a polar solvent.
7. The purification process according to claim 5 or 6, wherein the polar solvent is ethyl acetate, tert-butyl methyl ether, 2-propanol, or ethanol.
8. A purification process according to any one of claims 1to 7, wherein the HPLC analysis is a reversed phase HPLC analysis.
9. The purification method according to any one of claims 1to 8, wherein the component is a component containing 98% or more of tafluprost.
10. The purification method according to any one of claims 2to 9, wherein the filtration is performed using a filter having a pore size of 0.5 μm or less.
11. The purification method according to any one of claims 2to 10, wherein the solvent for dissolving the residue is ethyl acetate, t-butyl methyl ether, 2-propanol or ethanol, or a mixed solvent of ethyl acetate, t-butyl methyl ether, 2-propanol or ethanol and a nonpolar solvent.
12. The purification method according to claim 11, wherein the solvent for dissolving the residue is ethyl acetate or a mixed solvent of ethyl acetate and a nonpolar solvent.
13. Purification process according to claim 11 or 12, in which the apolar solvent is n-hexane or n-heptane.
14. The purification method according to any one of claims 2to 13, wherein the final ultimate vacuum degree is 1torr or less.
15. The purification method according to any one of claims 2to 14, wherein the residual solvent concentration of n-hexane after the step of distilling off the solvent of the filtrate is 290ppm or less, and the residual solvent concentrations of n-heptane, ethyl acetate, tert-butyl methyl ether, 2-propanol, or ethanol are 5000ppm or less, respectively.
16. A method for producing tafluprost, which comprises subjecting a crude product of tafluprost to the purification method according to any one of claims 1to 15.
17. Tafluprost obtained by the production method according to claim 16.
18. A pharmaceutical preparation comprising the tafluprost of claim 17 as an active ingredient.
19. A pharmaceutical product for preventing or treating an ocular disease, which comprises the tafluprost of claim 17 as an active ingredient.
20. The pharmaceutical product according to claim 19, wherein the ocular disease is glaucoma or ocular hypertension.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210974278.3A CN115448840A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202210974557.XA CN115322094A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202210975458.3A CN115322095A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202110111991.0A CN112851510B (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202210974156.4A CN115385793A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
PCT/JP2021/018791 WO2022162967A1 (en) | 2021-01-27 | 2021-05-18 | Method for purifying tafluprost |
KR1020237022476A KR20230129019A (en) | 2021-01-27 | 2021-05-18 | Method for purifying tafluprost |
KR1020227045640A KR102552337B1 (en) | 2021-01-27 | 2021-05-18 | Purification method of tafluprost |
JP2021539992A JP7192999B1 (en) | 2021-01-27 | 2021-05-18 | Purification method of tafluprost |
JP2022195313A JP2023054794A (en) | 2021-01-27 | 2022-12-07 | Tafluprost purification method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110111991.0A CN112851510B (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210974156.4A Division CN115385793A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202210974278.3A Division CN115448840A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202210974557.XA Division CN115322094A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202210975458.3A Division CN115322095A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112851510A true CN112851510A (en) | 2021-05-28 |
CN112851510B CN112851510B (en) | 2022-07-19 |
Family
ID=75985973
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210974557.XA Pending CN115322094A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202210974156.4A Pending CN115385793A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202210974278.3A Pending CN115448840A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202210975458.3A Pending CN115322095A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202110111991.0A Active CN112851510B (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210974557.XA Pending CN115322094A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202210974156.4A Pending CN115385793A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202210974278.3A Pending CN115448840A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
CN202210975458.3A Pending CN115322095A (en) | 2021-01-27 | 2021-01-27 | Purification method of tafluprost |
Country Status (4)
Country | Link |
---|---|
JP (2) | JP7192999B1 (en) |
KR (2) | KR102552337B1 (en) |
CN (5) | CN115322094A (en) |
WO (1) | WO2022162967A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116124936B (en) * | 2023-01-03 | 2024-01-30 | 苏州欧康维视生物科技有限公司 | Detection method for related substances of tafluprost |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103588692A (en) * | 2012-08-15 | 2014-02-19 | 台湾永光化学工业股份有限公司 | Method for purifying fluorine-containing prostaglandin using preparative high performance liquid chromatography |
CN109053452A (en) * | 2018-08-23 | 2018-12-21 | 扬子江药业集团有限公司 | A kind of preparation method of tafluprost bulk pharmaceutical chemicals |
CN112209863A (en) * | 2020-07-07 | 2021-01-12 | 浙江尖峰药业有限公司 | Large-scale preparation method of tafluprost |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3480549B2 (en) * | 1996-12-26 | 2003-12-22 | 参天製薬株式会社 | Difluoroprostaglandin derivatives and uses thereof |
JP5512930B2 (en) | 2007-03-26 | 2014-06-04 | 株式会社半導体エネルギー研究所 | Method for manufacturing semiconductor device |
KR100850926B1 (en) | 2007-04-02 | 2008-08-08 | 주식회사 대우일렉트로닉스 | Pocket assembly for refrigerators |
IT1392492B1 (en) * | 2008-12-24 | 2012-03-09 | Ind Chimica Srl | PROCESS FOR THE PURIFICATION OF LATANOPROST, SYNTHETIC ANALOGUE OF PROSTAGLANDINA PGF2ALFA. |
US20150011755A1 (en) | 2012-02-07 | 2015-01-08 | Dr. Reddys Laboratories Limited | Amine salts of prostaglandin analogs |
US20140046086A1 (en) | 2012-08-10 | 2014-02-13 | Scinopharm (Changshu) Pharmaceuticals, Ltd. | Process for the preparation of tafluprost and intermediates thereof |
US9115109B2 (en) | 2013-08-15 | 2015-08-25 | Chirogate International Inc. | Processes and intermediates for the preparations of isomer free prostaglandins |
HU231214B1 (en) * | 2014-03-13 | 2021-11-29 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | New process for preparing high purity prostaglandins |
WO2016090461A1 (en) | 2014-12-10 | 2016-06-16 | Apotex Inc. | Salts of prostaglandin analog intermediates |
CN108299192A (en) | 2017-01-10 | 2018-07-20 | 江苏恒瑞医药股份有限公司 | A kind of metal salt compound crystal form and preparation method thereof of tafluprost acid |
-
2021
- 2021-01-27 CN CN202210974557.XA patent/CN115322094A/en active Pending
- 2021-01-27 CN CN202210974156.4A patent/CN115385793A/en active Pending
- 2021-01-27 CN CN202210974278.3A patent/CN115448840A/en active Pending
- 2021-01-27 CN CN202210975458.3A patent/CN115322095A/en active Pending
- 2021-01-27 CN CN202110111991.0A patent/CN112851510B/en active Active
- 2021-05-18 JP JP2021539992A patent/JP7192999B1/en active Active
- 2021-05-18 KR KR1020227045640A patent/KR102552337B1/en active IP Right Grant
- 2021-05-18 WO PCT/JP2021/018791 patent/WO2022162967A1/en unknown
- 2021-05-18 KR KR1020237022476A patent/KR20230129019A/en active Search and Examination
-
2022
- 2022-12-07 JP JP2022195313A patent/JP2023054794A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103588692A (en) * | 2012-08-15 | 2014-02-19 | 台湾永光化学工业股份有限公司 | Method for purifying fluorine-containing prostaglandin using preparative high performance liquid chromatography |
CN109053452A (en) * | 2018-08-23 | 2018-12-21 | 扬子江药业集团有限公司 | A kind of preparation method of tafluprost bulk pharmaceutical chemicals |
CN112209863A (en) * | 2020-07-07 | 2021-01-12 | 浙江尖峰药业有限公司 | Large-scale preparation method of tafluprost |
Also Published As
Publication number | Publication date |
---|---|
CN115385793A (en) | 2022-11-25 |
JPWO2022162967A1 (en) | 2022-08-04 |
KR20230012069A (en) | 2023-01-25 |
JP2023054794A (en) | 2023-04-14 |
WO2022162967A1 (en) | 2022-08-04 |
CN112851510B (en) | 2022-07-19 |
CN115448840A (en) | 2022-12-09 |
JP7192999B1 (en) | 2022-12-20 |
KR20230129019A (en) | 2023-09-05 |
KR102552337B1 (en) | 2023-07-07 |
CN115322095A (en) | 2022-11-11 |
CN115322094A (en) | 2022-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2941087A1 (en) | Ibrutinib solid forms and production process therefor | |
US6432936B1 (en) | Crystalline 1α-hydroxyvitamin D2 and method of purification thereof | |
CN112851510B (en) | Purification method of tafluprost | |
AU2017224165A1 (en) | Process for preparing terpinene-4-ol | |
CN111183127B (en) | Cocrystal of cannabidiol | |
EP3116854B1 (en) | New process for the preparation of high purity prostaglandins | |
JP2013028630A (en) | Pharmaceutical composition comprising temozolomide ester | |
AU717568B2 (en) | Crystals of a vitamin D derivative and a method for the preparation thereof | |
JP2016183193A (en) | Solid state forms of fidaxomicin and processes for preparation thereof | |
JP2016222667A (en) | Crystalline fosaprepitant dicyclohexylamine salt and its preparation | |
US6835723B2 (en) | 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form | |
EP4056555A1 (en) | Method for purifying tafluprost | |
Uray et al. | tert-Butyl esters and ethers of (R, R)-tartaric acid | |
EP2630121A1 (en) | (20r,25s)-2-methylene-19,26-dinor-1alpha, 25-dihydroxyvitamin d3 in crystalline form | |
CN104230991A (en) | Method for controlling palladium residue in fosaprepitant dimeglumine | |
EP2736915A1 (en) | New crystalline forms of tulathromycin | |
EP3026042B1 (en) | Stabilized 1,25-dihydroxyvitamin d2 and method of making same | |
EP2160376A2 (en) | Novel crystalline forms of atovaquone | |
EP3604284A1 (en) | Crystalline eltrombopag monoethanolamine salt form d | |
JP6894945B2 (en) | Lubiprostone crystals and their preparation methods | |
AU2012268858B2 (en) | Crystallization of 1a-hydroxy-2-methylene-18,19-dinor-homopregnacalciferol | |
JP2009520753A (en) | Process for the production of pure form of α-chiral chloromethyl compounds | |
EP3789377A1 (en) | A catalytically continuous flow pauson-khand reaction without carbon monoxide gas | |
KR100554560B1 (en) | Crystals of vitamin d derivatives and process for the preparation thereof | |
JP3210683B2 (en) | Isomer separation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |